LabCorp is diversifying. The big diagnostics player has swooped in to buy the contract research organization Covance for $6.1 billion in cash and stock, confident that a combination of its expertise with Covance’s approach to contract drug development will make for a successful merger.

…read more

Source: UPDATED: $6B Covance buyout puts LabCorp in the CRO biz


0 No comments